Study Group: Physicians who Treat Cystic Fibrosis (US)(?)
Council Members in this Study Group: 130
Request a survey with this Study Group
Leading Experts in this Study Group
Ass. Professor in Medicine
University of North Carolina at Chapel Hill School of Medicine - CC
Ray Coakley, MD PhD, is a physician scientist / pulmonary & critical care specialist at the University of North Carolina, Chapel Hill. His clinical and research focus is on COPD, cystic fibrosis, lung transplantation and PAH. Specific research expertise includes airway epithelial ion/fluid transport...
Robert Aris, MDAssociate Professor of Medicine
University of North Carolina Chapel Hill - CC
Robert Aris, MD, is an Associate Professor of Medicine at the University of North Carolina Chapel Hill. He is the Director of the Pulmonary Hypertension Program, the Lung Transplant Research Program and Inpatient Pulmonary Services. Dr. Aris has expertise in advanced lung diseases including cystic...
President
PSS Clinical Research
Warren Botnick, MD, FCCP, DABSM, is a Partner at Pulmonary and Sleep Specialists in Decatur, Georgia, since March 2003. He is Director of Critical Care Unit and Chief of Medicine at DeKalb Medical Center, Medical Director of Southern Sleep Technologies, and Co-Director of two sleep disorders centers...
Assistant Professor & Director
University of Florida
Kamal Mubarak, MD, is an Assistant Professor and Director of the Pulmonary Vascular Disease Program at University of Florida, Gainesville. Dr. Mubarak's clinical specialties include Internal Medicine, Critical Care Medicine, and Pulmonary Disease. He is involved in numerous clinical trials in treating...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
I agree with the premise of the article -- that diuretics may be underutilized as a cheap way to get the benefits of antihypertensives. However, more than 40% of my HTN patients are on diuretics, and I think the data presented in the NY Times article may be flawed. Here's why:
This phase III study was done without the benefit of conventional drug development with Phase I and Phase II studies (which would have provided more information about the effective dose) preceding it because pharmacokinetic date from IV and SC dosing studies were used to extrapolate for the...
While functional class II (FC II) PAH patients have been included in previous clinical trials, the EARLY trial is the first study to concentrate (ie recruit exclusively) FC II PAH patients. This is important because the definition of functional class II is that a patient has a sight...
This Circulation paper is the first peer reviewed data on the 2 pivotal Phase III trials on ambrisentan that lead the FDA to approving it for the treatment of PAH in July 2007. This paper is critically important since all new research needs to withstand the rigor of peer-review for...
Study will be ridiculed. 1) Comparator drug is not appropriate. 2) Not an outcomes study. 3) Time frame too short to be clinically significant. 4) Drug too expensive for first line use. 5) Long term safety not established.
GLG InstituteSM Seminars with this Study Group's Leading Experts(?)
Recent Seminars
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Academic Institution*
- Non-Academic Community Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Physician - Division Head
- Professor
- Owner
- Partner
- Medical Director
- Physician - Fellow
- Director
- President
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms